---

High prevalence of acute psychotic agitation in psychiatric emergency centers, necessitates finding an medication with less side effects and more efficacy. Concerning the reports about the efficacy of atypical antipsychotics (Even in oral route) in such cases. We decided to examine the efficacy of these drugs in comparison with older ones (Oral Risperidon plus Lorazepam and Haloperidol (IM) plus Lorazepams. The sample population included 60 acute psychotic agitated patients admitted to emergency room of Ebne-Sina psychiatric center. The exclusion criteria were seizure disorder-pregnancy-substance abuse, developmental disorders and other major medical problems. These patients were randomly divided in two groups. The first group was given Haloperidol (5 mg/IM) plus Lorazepam (2 mg/PO) and in the second group, Risperidon (2 mg/PO) plus Lorazepam (2 mg/PO) were administered remission was assessed based on the total score and scores of subclasses of PANSS including: Hostility, incooperativeness hallucinatory behaviors, impulse dyscontrol and excitement on time zero, 30 and 60 minutes. The results were analyzed using the proper test analyzer. Significant decrease in PANSS scores were observed in each group (P<0.001). There was no significant differences in total score and scores of subclasses between 2 groups. 3 patients of each group needed additional dose 1 hour after the first one. The mean time to induce sleep in Haloperidol group was 60 minutes (SD: 33 m) and in the Risperidon group 55 minutes (SD: 34 m). The present study similar to previous ones showed that the efficacy Risperidon plus Lorazepam (PO) in the control psychotic agitation was equal to that of intramuscular Haloperidol plus oral Lorazepam.

---

Background and Objective: Schizophrenia is a disorder characterized by a chronic recurrent course. Despite the availability of an ever-expanding range of typical and atypical antipsychotics, a substantial proportion of patients with schizophrenia show a partial or total lack of response to antipsychotic monotherapy. This study was done to evaluate the clinical effects of Ginkgo biloba as an adjunct to the Risperidone and Biperiden in the treatment of chronic schizophrenic patients. Materials and Methods: This randomized clinical trial study was carried out on 60 chronic schizophrenic patients in Sina hospital Shahrekord, Iran during 2009-10. Schizophrenia was diagnosed by DSM-IV-TR criteria. Subjects were randomly divided into intervention and control groups. Two groups were matched according to the age, sex, education, duration of illness. Patients in interventional group received Risperidone up to 6mg/day, Biperiden 4mg/day and Ginkgo biloba 240 mg/day for 12 weeks. The control group received Risperidone up to 6mg/day and Biperiden 4mg/day for 12 weeks. The scales for assessment of positive symptoms (SAPS) and assessment of negative symptoms (SANS) were recorded in prior, 6th and 12th weeks. Data analyzed by using SPSS-15 and student t-test. Results: The mean score of positive symptoms were 55.7±2.1 and 74.4±2.3 in interventional and control groups, respectively (P<0.05) after 12 weeks. The mean score of negative symptoms were 63±1.3 and 69.3±1.8 in interventional and controls, respectivley (P<0.05) after 12 weeks. Conclusion: This study suggested that the use of Ginkgo biloba as an adjunct to Respridone and Biperiden was more effective than Risperidone with Biperiden regimen improving psychological condition of chronic schizophrenic patients.